Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease ; volume:16 ; number:1 ; day:17 ; month:8 ; year:2023 ; pages:1-9 ; date:12.2023
Journal of hematology & oncology ; 16, Heft 1 (17.8.2023), 1-9, 12.2023

Creator: Heitmann, Jonas S.
Schlenk, Richard Friedrich
Dörfel, Daniela
Kayser, Sabine
Döhner, Konstanze
Heuser, Michael
Thol, Felicitas
Kapp-Schwoerer, Silke
Labrenz, Jannik
Edelmann, Dominic
Märklin, Melanie
Vogel, Wichard
Bethge, Wolfgang
Walz, Juliane S.
Große-Hovest, Ludger
Steiner, Martin
Jung, Gundram
Salih, Helmut R.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13045-023-01490-w

URN: urn:nbn:de:101:1-2023110413302238239858

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Heitmann, Jonas S.
Schlenk, Richard Friedrich
Dörfel, Daniela
Kayser, Sabine
Döhner, Konstanze
Heuser, Michael
Thol, Felicitas
Kapp-Schwoerer, Silke
Labrenz, Jannik
Edelmann, Dominic
Märklin, Melanie
Vogel, Wichard
Bethge, Wolfgang
Walz, Juliane S.
Große-Hovest, Ludger
Steiner, Martin
Jung, Gundram
Salih, Helmut R.
SpringerLink (Online service)

Other Objects (12)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Hochschulschrift

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hochschulschrift

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Hochschulschrift

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Hochschulschrift

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hochschulschrift

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Hochschulschrift

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Hochschulschrift

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hochschulschrift

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Hochschulschrift

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurina

Measurable residual disease

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

FLT3-ITD regulated miRs in AML

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Have we been qualifying measurable residual disease correctly?

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations

Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien

Related objects

Reset password